Martin McLaughlin

6PUBLICATIONS
32CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Radiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 03, 2026
Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

Victoria Roulstone, Joan Kyula, Elizabeth Appleton

|Dec 12, 2024
CXCL12-Targeted Immunomodulatory Gene Therapy Reduces Radiation-Induced Fibrosis in Healthy Tissues.

James T Paget, Joseph A Ward, Andrew R McKean

|Mar 26, 2022
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.

Galabina Bozhanova, Jehanne Hassan, Lizzie Appleton

|Mar 22, 2022
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.

Emmanuel C Patin, Magnus T Dillon, Pablo Nenclares

|Mar 13, 2020
Inflammatory microenvironment remodelling by tumour cells after radiotherapy.

Martin McLaughlin, Emmanuel C Patin, Malin Pedersen

|Jan 26, 2018
Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.

Aadil A Khan, James T Paget, Martin McLaughlin

Pageof 1

Frequent Collaborators

4 joint publications

Alan Melcher

4 joint publications

Kevin J Harrington

3 joint publications

Victoria Roulstone

3 joint publications

Emmanuel Christian Patin